Stocktoria
IOVANCE BIOTHERAPEUTICS, INC. IOVA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2008-06-20
IOVANCE BIOTHERAPEUTICS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -153.1% | -240.9% | -38735.0% | — | — |
| Net margin | -148.4% | -226.8% | -37345.4% | — | — |
| FCF margin | -127.6% | -221.9% | -32305.3% | — | — |
| Return on assets | -42.8% | -40.9% | -56.9% | -59.6% | -44.0% |
| Return on equity | -56.0% | -52.4% | -76.0% | -79.2% | -55.1% |
| Current ratio | 3.20 | 3.74 | 2.79 | 5.24 | 5.69 |
| Revenue growth | 60.6% | 13699.0% | — | — | — |
Source: SEC EDGAR filings · CIK 0001425205 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.